MedTrace Logo

Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka

NCT01551537 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2013-09-09

No results posted yet for this study

Summary

This PMS study aims to collect safety and reactogenicity data of Cervarix in the local population as per the licensing requirement of the Sri Lankan regulatory authority.

Conditions

  • Human Papillomavirus Infection

Interventions

OTHER

Cervarix data collection

Safety monitoring: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact.

OTHER

Data Collection

All adverse events will be recorded by diary card, follow-up visit or telephone contact.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
10 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-04-30
Completion
2014-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01551537 on ClinicalTrials.gov